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Abstract
T-cell responses (proliferation, intracellular cytokine synthesis and IFNc ELISPOT) against human papillomavirus 16 (HPV16)
E2 peptides were tested during 18 months in a longitudinal study in eight women presenting with HPV16-related usual
vulvar intraepithelial neoplasia (VIN) and their healthy male partners. In six women, anti-E2 proliferative responses and
cytokine production (single IFNc and/or dual IFNc/IL2 and/or single IL2) by CD4+ T lymphocytes became detectable after
treating and healing of the usual VIN. In the women presenting with persistent lesions despite therapy, no proliferation was
observed. Anti-E2 proliferative responses were also observed with dual IFNc/IL2 production by CD4+ T-cells in six male
partners who did not exhibit any genital HPV-related diseases. Ex vivo IFNc ELISPOT showed numerous effector T-cells
producing IFNc after stimulation by a dominant E2 peptide in all men and women. Since the E2 protein is absent from the
viral particles but is required for viral DNA replication, these results suggest a recent infection with replicative HPV16 in male
partners. The presence of polyfunctional anti-E2 T-cell responses in the blood of asymptomatic men unambiguously
establishes HPV infection even without detectable lesions. These results, despite the small size of the studied group, provide
an argument in favor of prophylactic HPV vaccination of young men in order to prevent HPV16 infection and viral
transmission from men to women.
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Introduction
Human papillomaviruses 16 (HPV16) is involved in more
than 50% of uterine cervical cancers and is the second cause of
mortality by cancer in women worldwide, with an incidence of
500 000 cases and 230 000 deaths annually [1,2]. These tumors
are preceded by grade 3 intraepithelial neoplasia (CIN3),
diagnosed on the basis of Pap smears and followed up by
colposcopy and biopsies. We were interested by usual vulvar
intraepithelial neoplasia (VIN) lesions which are HPV-related
and commonly resemble persistent anogenital warts that are
often multifocal pigmented papular lesions. Usual VIN is
characterized by the presence of poorly differentiated or
undifferentiated basal cells and highly atypical squamous
epithelial cells [3]. The involvement of the entire thickness of
the epithelium defines its grade 3 (VIN3), in which high-risk
HPV (HR-HPV) types, essentially HPV16, play a direct role in
up to 91% of the cases [4]. The viral E2 protein is a major
regulator of viral replicative cycle. It is required, together with
the E1 helicase, for both regulation of transcription and
replication of viral DNA [5]. In contrast, E2 protein is generally
undetectable in cancer due to preferential integration of the
viral genome in the cell genome and disruption of the E2 open
reading frame [6,7]. Therefore E2 protein is a marker of viral
infection specific of the early stages of viral gene expression in
infected cells. This has formally been demonstrated in a recent
work that showed a strong staining of the E2 protein in the
intermediate differentiated layers of HPV16-infected tissues and
low grade CIN of the cervix [8]. These data indicate that
HPV16 E2 is highly expressed in low grade lesions and
therefore represents a marker for HPV infection even before
any clinical manifestation. The immune response specific of the
two oncogenic viral proteins E6 and E7 has already been
analyzed in studies aiming at understanding the local immune
microenvironment in VIN as well as in cervical cancer and
their precursor stages [9–11]. However these viral proteins,
although probably expressed from the early stages of replicative
cycle, may be expressed at levels too low to be useful markers
for HPV infection. Previous experiments done with HPV16 E6
and E7 in VIN indicated that the blood-T cell responses against
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response toward an earlier more abundant viral protein would
be higher. Previous experiments performed in women infected
by HPV16 with or without HPV16-induced vulvar or cervical
lesions strengthen this hypothesis although no time course study
was performed and results were sometimes controversial. Blood
proliferative T-cell responses against HPV16 E2 peptides were
observed in 50% of healthy women, who presumably cleared
HPV16 infection previously [16] and in 9 out of 22 regressive
CIN3 cases [17]. In another study, 50% of women affected with
usual VIN showed anti-E2 proliferative responses [18]. In
contrast, the lack of anti-E2 proliferative responses was reported
in 16 out of 18 patients (89%) affected with usual VIN lesions
[19] and in 7 out of 8 and in 9 out of 12 women affected with
CIN3 [16,17]. The aim of the present study was to
longitudinally follow, over an 18 months period, anti-E2 blood
T cell responses in 8 women presenting with usual HPV16-
related VIN in order to search for a relationship between blood
anti-E2 T-cell responses and healing. We also analyzed HPV
infection and anti-HPV16 E2 blood T-cell responses in their
asymptomatic male partners who were regularly and chronically
exposed to HPV16 during sexual intercourses with their wives.
Indeed, it has been previously demonstrated that men are
vectors of oncogenic HPV infection [20]. However, while HPV
infection was found in 71 to 90% of the partners of women
presenting with HPV infections [21,22], only 52% harbored the
same HPV subtypes [23]. Moreover, penile intra-epithelial
neoplasia is rare and can only be detected in less than 2% of
the men in contact with oncogenic HPV [24]. In the present
study, we hypothesized that male partners exposed to replicative
HPV16 could develop immunologic responses against the early
E2 viral protein allowing control of infection.
Results
HPV16-E2 Specific Proliferative T-cell Responses in
Women Correlate with the Evolution of the Lesion
Eight women presenting with VIN were included in the study.
Two were treated and cleared their lesions within a few months
before study entry (F#2 and F#4), four were symptomatic at
study entry and cleared their VIN during the study (F#3, F#5,
F#6 and F#8) while two had persistent lesions despite therapy
(F#1 and F#7).
In these two latter women (F#1, F#7) with persistent VIN
lesions during the whole study, E2 peptide specific proliferative T-
cell responses remained undetectable (Figure 1A).
In the four women (F#3, #5, #6, #8) who presented with
usual VIN lesions at entry in the study and cleared them under
treatment, no proliferative responses were observed at early stages
(Figure 1A) whereas they became detectable at the time of clinical
clearance of the lesions (at month 6 (M6) for F#3, #6, #8 and at
M12 for F#5) (Figure 1B). These responses were directed against
E2-1 to E2-5, E2-9 to E2-11 pools, with stimulation index (SI)
ranging from 3 to 7.3. Peptides 94–108 (SI=3.8) for E2–4 pool
and 335–350 (SI=3) for E2-11 pool were individualized as the
recognized peptides in F#6 while peptide 301–315, included in
E2-10, was recognized (SI=3.1) by F#8. These responses were
most probably mediated by CD4+ T-cell as they were observed in
CD4+ T lymphocyte-enriched fractions in F#3 (data not shown).
Similarly, positive responses were observed in the two women
who presented with VIN lesions three and four months before
entering the study but were asymptomatic after therapy at entry
(F#2, #4) (Figure 1B). The E2-3 pool was recognized in these two
women with SI of 4.7 and 10.9 at M6 and M12 respectively. Two
reactive 15-mer peptides were identified in this pool: peptide 68–
82 and peptide 80–94 recognized with SI of 3.7 and 4.9,
respectively. E2–2, E2–4, E2–9 and E2–10 pools were also
targeted by T lymphocytes from F#4. Peptide 34–48 (SI=3.1)
was identified in the E2–2 pool and peptide 94–108 (SI=13.1) in
the E2–4 pool.
Patients who cleared VIN before or during follow up displayed
a strong proliferative T-cell response (6/6), while such a response
was undetectable in women having classic VIN lesions (0/6)
(p=0.002, Fisher exact test).
HPV16-E2 Specific Proliferative T-cell Responses in Male
Partners
None of the eight partners presented with any HPV lesions and
HPV16 was undetectable by genital brushing and HPV DNA
typing in all but one (M#8) cases (Table 1). All but one (M#5)
partners of the women with usual VIN lesions had proliferative
responses against E2 peptides (Figure 2). Cell proliferations were
observed after stimulation by peptides from E2-3 pool in five of
them (M#1, #2, #3, #4, #6), by peptides from E2-4 in two
(M#3, #7) and by peptides from E2-1 in M#1, E2-2 in M#7,
E2-8 in M#7, E2-10 in M#1 and E2-11 in M#8. The most
strongly stimulating peptide in the E2-3 pool was peptide 68–82
with SI=10.5 and 15.5 in M#1 and M#3 respectively. Other
peptides recognized in the E2-3 pool were peptide 73–88 (SI=6.1
and 3.5 in M#3 and M#6 respectively), peptide 60–74 (SI=7.5
in M#4) and peptide 80–94 (SI=3.3 in M#4). In E2-4 and E2-2
pools, peptides 99–114 (SI=5.2 in M#7), 108–122 (SI=6.2 in
M#7), 113–128 (SI=4.9 in M#3) and 47–61 (SI=3.4 in M#7)
were also identified as immunogenic peptides.
In M#1 and M#4, proliferative responses were observed in
CD4+ T lymphocyte-enriched fractions or in CD8-depeleted T-
cell fraction (data not shown).
Taken together, these data indicate that, despite the absence of
detectable HPV-related lesions, all male partners but one (M#5)
showed E2-specific proliferative T cell responses. It is important to
note that M#5 had rheumatoid arthritis treated by low doses of
methotrexate (10 mg per week) and corticosteroids (8 mg per day)
for 10 years.
Intracellular Cytokine Staining in Proliferative T-cell
Responder Women
In order to further characterize the E2-specific responses in
patients clearing usual VIN after treatment, we analyzed IFNc
and IL2 production by HPV16 E2-stimulated CD4+ T-cells
from women whose peripheral blood mononuclear cells (PBMC)
displayed positive proliferative responses (F#2, #3, #4, #5, #6
and #8). In all six women, intracellular staining for IFNc and/
or IFNc/IL2 and/or IL2 by CD4+ T lymphocytes was
observed in the presence of at least one peptide or a pool of
peptides identified by proliferation tests (Figure 3). IFNc only
was synthesized in the presence of peptide 68–82 by F#2, of
pool E2-2 by F#4, of pool E2-3 or peptide E2-5 by F#3, of
pool E2-1 by F#5 and of peptide 301–315 by F#8. Dual
IFNc/IL2 response after stimulation by one peptide or a pool
of peptide was observed in women F#2 (peptide 68–82), who
entered the study after tumor treatment and in women F#3
(pool E2-5), F#6 (pool E2-11 and peptide 335–350) and F#8
(peptide 301–315) at the time of the clearance of their lesion.
Synthesis of IL2 alone was observed in F#2 (peptide 68–82),
F#4 (peptide 94–108), F#3 (pool E2-5), F#5 (pool E2-1) and
F#8 (peptide 301–315).
Anti-HPV16 E2 T-Cell Responses in Couples
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Among the 7 male partners showing positive proliferative
responses, synthesis of single IFNc, dual IFNc/IL2, and single IL2
by CD4+ T-cells in the presence of at least one peptide or a pool of
peptides was evidenced in six cases (M#1, #2, #3, #6, #7, #8)
(Figure 4). High percentages of such CD4+ T-cells were found in
the partners in whom proliferative assays exhibited SI superior to 5
(peptide 68–82 in M#1, peptide 73–88 in M#3, peptide 99–114
in M#7, pool E2-11 in M#8). Intracellular cytokine production
was undetectable in M#4.
Ex vivo IFNc ELISPOT assays in Usual VIN Women
IFNc ELISPOT responses were found in symptomatic women
(Figure 5A), including F#1 and F#7 who suffered from persistent
VIN lesions, and in three women before the time of clinical
clearance under treatment (F#3, F#5, F#8). More than 1000
SFC/10
6 PBMC against E2-10 were observed in these symptom-
atic women at different time-points, reflecting a high number of
specific effector IFNc-producing T cells. Significant IFNc ELI-
SPOT response contemporary to clinical VIN lesions was not
detected in F#6 only. IFNc ELISPOT were also found in all
asymptomatic women (Figure 5B), including F#2 and F#4 who
were asymptomatic at study entry and in four women after clinical
clearance (F#3, F#5, F#6, F#8), with a number of cells below
850/10
6 PBMC in all but one patients (F#5).
Three women had IFNc ELISPOT responses against one pool
of peptide (F#2, #3 and #5), one against two pools (F#1), two
against three pools (F#6 and #7) and two against five pools (F#4
and #8) (Figure 5A and 5B). Among these pools, E2-10 was
recognized by cells from all women, with more than 1000 spot
forming cells (SFC)/10
6 PBMC in five women (F#1, #3, #5, #7,
#8), 500 to 1000 SFC in two women (F#2, #6) and about 100
SFC in the last case (F#4). In this E2-10 pool, peptide E2 309–323
was always the recognized peptide (data not shown).
Ex vivo IFNc ELISPOT assays in Male Partners
PBMCs from all the male partners exhibited a positive response
after stimulation by one pool in four of them (M#1, #3, #5, #7),
four pools in one (M#2), five pools in two (M#4 and #6) and all
eleven pools of E2 peptides in the latter case (M#8) (Figure 6). The
immunodominant E2 peptides pool was E2-10 with a response
greater than 1000 SFC/10
6 PBMC in five individuals (M#1, #4,
#5, #7, #8) and up to 700 SFC in another partner (M#2).
PBMCs from M#3 and M#6 also showed positive responses
against the same pool E2-10 with 230 and 400 SFC respectively.
Peptide 309–323 was identified as the dominant peptide recog-
nized in this E2-10 pool (data not shown). We therefore detected a
strong anti-E2 response in all male partners, more specifically
against a peptide located in the C-terminal part of the protein that
was also immunodominant in the samples from the women
partners.
Discussion
In the present work, we studied HPV16 E2 protein because
of its early and strong expression [8]. E2 is a larger protein
Figure 1. Anti-HPV16 E2 peptide proliferative responses in women. T-cell proliferation induced by E2 peptide pools were studied with
PBMCs from A: women presenting with usual VIN either during the whole study (F#1 and F#7) or at study entry and up to the healing after
treatment (F#3, F#6, F#8 before M6, F#5 before M12) and B: asymptomatic women having cleared their usual VIN after treatment (F#2, F#4 before
their entry in the study, F#3, F#6, F#8 from M6, F#5 from M12). SI is represented by the cpm in peptide-stimulated cells/cpm in negative control
wells (without peptide). Each bar represents SI against a pool of E2 peptide or positive control (+) obtained from PBMCs sampled at M0 (blue), M6
(red), M12 (yellow) and M18 (turquoise blue). Proliferative responses with SI .3 were scored as positive, provided that cpm in the negative control
was above 500. The values of positive SI for E2 pools are indicated in black near the corresponding bar. Responses to 15 mer peptides comprised in
the various peptide pools are shown, superposed to the response to the pool, in another color. The SI values for these peptides are indicated using
the same colors near the corresponding bars.
doi:10.1371/journal.pone.0036651.g001
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than E6 and E7 [16,25]. Therefore looking for an E2-specific
response appeared to be more sensitive. In addition, E2 is
required for viral replication [26] and the detection of E2-
specific T cell responses is the signature of this event [25]. The
study of anti-E2 T-cell responses is thus appropriate in the early
phases of HPV16 infection or for pre-malignant lesions as usual
VIN. We observed proliferative responses to HPV16-E2
antigens in 6 out of 8 women presenting with usual HPV16-
associated VIN. Two of them were asymptomatic at study entry
(treated 3 and 4 months before by laser or electrocoagulation,
respectively) whereas in the four other women proliferative
responses strongly linked with ongoing clearance of the lesion
after treatment (imiquimod or laser). In contrast, no E2-specific
responses were detected in patients with persistent lesions and in
the four other ones before they underwent VIN treatment.
Then the association between the disappearance of the HPV-16
induced vulvar lesions under therapy and the development of
E2-specific proliferative T cell responses is striking. The
appearance of anti-E2 proliferative T-cell responses could be a
consequence of the release of E2 protein after local therapy, as
they did not occur spontaneously.
The six women who demonstrated proliferative responses also
had CD4+ T-cells synthesizing IL2 alone, IFNc alone or both
IFNc and IL2. Such a profile (presence of proliferating and
cytokine-producing polyfunctional population) suggests that these
Figure 2. Anti-HPV16 E2 peptide proliferative responses in male partners of women presenting with usual VIN. Proliferative assays
were performed using PBMCs in presence of pools of E2 peptides. SI is represented by the cpm in peptide-stimulated cells/cpm in negative control
wells (without peptide). Each bar represents SI against a pool of E2 peptide or positive control (+) obtained from PBMCs sampled at M0 (blue), M6
(red), M12 (yellow) and M18 (turquoise blue). Proliferative responses with SI .3 were scored as positive, provided that cpm in the negative control
was above 500. The values of positive SI for E2 pools are indicated in black near the corresponding bar. Responses to 15 mer peptides comprised in
the various peptide pools are shown, superposed to the response to the pool, in another color. The SI values for these peptides are indicated in the
same colors near the corresponding bars.
doi:10.1371/journal.pone.0036651.g002
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responses as previously described by Harari [27].
Moreover, all women, whether they cleared or not their lesion
after treatment, had very high number of anti-HPV16-E2 T-cells
as tested by ex vivo IFNc ELISPOT. The presence of a
monofunctional population producing IFNc only, without detect-
able proliferation observed in the women presenting with
persistent lesions (F#1, #7 and #3, #5, #6, #8 before
treatment) is consistent with the presence of effector T-cells and
an uncontrolled HPV16 infection. This is in agreement with
previous study showing that the detection of specific immune
responses against E2 peptides by IFNc ELISPOT did not correlate
with either HPV16 control or VIN or CIN1 clearance [25].
Moreover, after local therapy and healing, the number of IFNc-
producing T-cells decreased, as observed in women F#3 and
F#8. The latter observation suggests that the monofunctional T-
cell population producing IFNc only depends on the quantity of
HPV16-E2 protein synthesized.
Strong anti-E2 IFNc ELISPOT responses against HPV16 309–
323 E2 peptide were found in all women. This 15-mer peptide,
included in the E2-10 peptides pool, shares more than 70% amino
acids (by BLAST analysis) only with cutaneous HPV2 and 27 and
with mucosal HPV55. Five of eight women had a past history of
common warts (F#1, #4, #5, #6, #7) (Table 1). In order to
exclude a possible cross-reactivity between HPV types, we
performed ex vivo IFNc ELISPOT assays against E2 309–323
peptide from HPV2, 27 and 55 that were all negative (Table 2).
Consequently, we conclude that the IFNc ELISPOT responses
against HPV16 309–323 E2 peptide are indeed specific for
HPV16.
In the absence of condom usage for at least 6 months, the male
partners of the eight women could be contaminated by HPV16.
HPV16 and HPV27 (a cutaneous HPV) were identified in genital
Figure 3. Intracellular cytokine synthesis to HPV16 E2 peptides
in proliferative T-cell female responders. The percentage of CD4+
T-cells synthesizing single IFNc, dual IFNc/IL2 or single IL2 was
measured in response to E2 peptide pools or E2 peptide and compared
to negative (no or irrelevant peptide) and positive controls (pool of
non-HPV viral peptides). Single IFNc responses are shown in blue, dual
IFNc/IL2 in red and single IL2 in green. Percentages of CD4+ responding
cells are in the same color as the cytokine(s) synthesized. The white
color represents the percentage of non responding cells among CD4+ T
lymphocytes. Responses were considered as positive when the
percentage of CD4+ T-cells synthesizing cytokines increased by at least
0.2% in the presence of the peptide as compared to negative control.
doi:10.1371/journal.pone.0036651.g003
Figure 4. Intracellular cytokine synthesis to HPV16 E2 peptides
in proliferative T-cell male responders. The percentage of CD4+ T-
cells synthesizing single IFNc, dual IFNc/IL2 or single IL2 was measured
in response to E2 peptide pools or E2 peptides and compared to
negative (no or irrelevant peptide) and positive controls (pool of non-
HPV viral peptides). Single IFNc responses are shown in blue, dual IFNc/
IL2 in red and single IL2 in green. Percentages of CD4+ responding cells
are shown using the same color as the cytokine(s) synthesized. The
white color represents the percentage of non responding cells among
CD4+ T lymphocytes. Responses were considered as positive if the
percentage of CD4+ T-cells synthesizing cytokines was at least 0.2%
higher in the presence of stimulating peptide(s) than in negative
control.
doi:10.1371/journal.pone.0036651.g004
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partners (M#8, #5) (Table 1). Such a prevalence of HPV16
contamination is similar to the one usually observed in male
partners of oncogenic HPV-infected women [23]. This does not
exclude the possibility that the other male partners could also be
infected either at undetectable levels or in anatomical sites not
sampled by the cytobrush.
We also observed HPV16-E2-specific proliferative responses
in seven male partners and intracellular synthesis of single
IFNc, dual IFNc/IL2 and single IL2 in six of them. These E2
specific T-cell responses in all male partners but two (M#4, #5)
indicate a striking link between the absence of HPV-related
lesions and the presence of spontaneous E2-specific proliferative
T-cell responses and single IFNc, dual IFNc/IL2, single IL2 T-
cell production, as previously described in other viral systems
[27,28]. Such a spontaneous polyfunctional anti-E2 T-cell
response could be due to an efficient presentation of viral
antigens by dendritic cells present in mucosal tissue and it is
tempting to speculate that E2-specific responses prevent
HPV16-related lesions. Therefore, spontaneous HPV16 control
could be related to the presence of polyfunctional memory
CD4+ T-cells in male partners.
Peptide 309–323 was also the dominant peptide detected in
IFNc ELISPOT assay in male partners. Indeed, high frequen-
cies (.500 SFC/10
6 PBMC) of blood effector T-cells, directed
against E2 309–323 peptide and synthesizing IFNc alone
without proliferative capacity were identified in the majority
of male partners (6/8) by ex vivo anti-E2 peptide IFNc
ELISPOT assays. The level of this response with very high
number of spots is similar to that observed during the chronic
phase of HIV infection characterized by highly replicative viral
reactivation [28,29]. In the six men tested, there was no
detectable cross reactivity with 309–323 E2 peptide from HPV2,
22 and 55, similarly to the findings in women (Table 2). Since
E2 protein is not encapsidated, stimulation of anti-E2 cellular
immune responses is a mark of the presence of viral replication
in infected cells. The high frequency of E2-specific T-cells
measured in partners of women with usual VIN demonstrates
that the virus effectively replicates in males.
In summary, the analysis of E2-specific T-cell responses is a
sensitive and reliable tool to analyze disease progression and the
natural history of HPV infection and premalignant lesions. In
women, polyfunctional T-cell responses featured by proliferative
responses and cytokine synthesis reflect memory CD4+ T-cell
population induced by VIN treatment. Monofunctional T-cell
responses restricted to ex vivo IFNc ELISPOT reflect the presence
of numerous HPV16 E2-specific effector T-cells but does not
correlate with control of HPV16 infection.
In the male partners, the presence of polyfunctional spontane-
ous T-cell proliferative responses with single IL2, dual IFNc/IL2,
and single IFNc memory T-cells against HPV16 E2 peptides in
the absence of detectable lesion despite HPV16 exposure suggests
an efficient and spontaneous control of genital HPV lesions. These
results are reminiscent of those described in Gambian prostitutes
who, despite frequent exposure to HIV showed strong anti-HIV
cytotoxic T-cell responses and remained uninfected [30]. Such
anti-HPV16 T cells responses may thus reflect the control of viral
infection.
We therefore demonstrate that, although not clinically detect-
able, HPV16 can replicate in men and induce a strong memory T
cell response against one of the early viral proteins. Despite the fact
that they were obtained in a small cohort of couples, our results
suggest that males are an important reservoir of genital HPVs and
provide an argument in favor of prophylactic HPV vaccination of
Figure 5. Ex vivo anti-HPV16-E2 peptide IFNc ELISPOT responses in women presenting with usual VIN. IFNc ELISPOT response to E2
peptide pools was studied using PBMCs from A: women presenting with usual VIN either during the whole study (F#1 and F#7) or at study entry and
up to the healing after treatment (F#3, F#6, F#8 before M6, F#5 before M12) and B: asymptomatic women having cleared their usual VIN after
treatment (F#2, F#4 before their entry in the study, F#3, F#6, F#8 from M6, F#5 from M12). Bars represent numbers of SFC/10
6 PBMCs against a
pool of E2 peptides, negative (0) and positive (+) controls obtained at M0 (blue), M6 (red), M12 (yellow) and M18 (turquoise blue). Standard deviation
of triplicates appears for each bar. Responses were considered significant when the mean number of SFC per 10
6 cells in the 3 experimental wells was
.3-fold the mean number of SFC in the negative control wells (PBMC alone) and .30 SFC/10
6 cells. Positive responses are identified by a black star
above the corresponding bar.
doi:10.1371/journal.pone.0036651.g005
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infection in men and thus fight against the spread of mucosal HPV
diseases in the population.
Materials and Methods
Ethics Statement
Promotion of the trial was made by INSERM (RBM 05–48).
Approbation of ethic committee from Ambroise Pare ´ hospital
was obtained December 6
th, 2005 (# 05 11 74). Every male
and female signed a written informed consent before starting
the study.
Inclusion and Exclusion Criteria of Couples
Every consecutive woman eligible for the study presented with
usual multifocal VIN proved by biopsy and documented HPV16
infection. Their current regular male sex partners were also
included. Additional inclusion criteria were sexual intercourses not
protected by condoms for at least 6 months. Exclusion criteria
were pregnancy, HIV seropositivity, CD4 T-cell count below 300/
ml and hemoglobin below 10 g/dl.
Female Patients
Eight 18–65 year-old (mean 46+11 years) consecutive women
entered the study (Table 1). They were followed up by doctors
M.MB, M.P and S.B at Cochin or Ambroise Pare ´ Hospitals at the
inclusion in the study (M0) and then every 6 months for 18 months
(M6, M12, and M18). Their VIN symptoms had appeared 5 to
180 months (mean 58+66 months) prior to inclusion. They
experienced numerous relapses despite multiple destructive
treatments (cryotherapy, electrocoagulation, surgery or laser) or
local topical therapy (5-fluorouracil, imiquimod). At study entry,
two women (F#2, #4) had no detectable vulvar lesions since 3 and
4 months respectively, after a curative treatment by imiquimod
and electrocoagulation. They did not show any recurrence during
the follow-up period of 18 months. Two women (F#3, #8) started
imiquimod therapy at study entry and cleared their usual VIN
lesions during the next 6 months. Two patients (F#5, #6) received
laser treatment either at the first visit (F#6) or one month before
the third visit (F#5) and cleared their infection at M6 and M12
respectively. The two last patients (F#1, #7) had persistent lesions
during the whole study. Patient F#7 was previously affected with
CIN3 treated by surgery. Patient F#6 had invasive cervical
carcinoma also treated by surgery. Five women had previously
Figure 6. Ex vivo anti-HPV16-E2 peptide IFNc ELISPOT responses in male partners of women presenting with usual VIN. IFNc ELISPOT
responses to E2 peptide pools were studied with PBMCs from male partners of women presenting with usual VIN. Bars represent numbers of SFC/10
6
PBMCs against a pool of E2 peptides, negative (0) and positive (+) controls obtained at M0 (blue), M6 (red), M12 (yellow) and M18 (turquoise blue).
Standard deviation of triplicates appears for each bar. Responses were considered significant when the mean number of SFC per 10
6 cells in the 3
experimental wells was .3-fold the mean number of SFC in the negative control wells (PBMC alone) and .30 SFC/10
6 cells. Positive responses are
identified by a black star above the corresponding bar.
doi:10.1371/journal.pone.0036651.g006
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most frequent HLA class II antigen (5/8 women), followed by
DR7 (3/8), DR15 (3/8) and DR11 (2/8). HPV-16 serological
assay was negative in two women (F#5, F#8) and positive in the
six other ones.
Male Partners
No male partners (mean age 50+14 years) had HPV-related
genital lesions at inclusion in the study and during follow-up
(Table 1). Samples for HPV typing were obtained by genital
brushing in distal urethra and prepuce internal surface, two areas
where HPV is most frequently found [21]. HPV16 and HPV27
were found in M#8 and #5 respectively. Two men had previous
history of HPV-related disease (common warts in M#1 and #4,
laryngeal papillomatosis in M#4). One man (M#5) had
rheumatoid arthritis treated by low doses of methotrexate
(10 mg per week) and corticosteroids (8 mg per day) for 10 years.
No predominant HLA class II allele was observed. HPV16
serological assay was negative in three males (M#2, M#4, M#5)
and positive in the five others.
Blood Samples
In accordance with the Ethics Committee of Ambroise Pare ´
hospital, 150 ml blood samples were collected at study entry for
each woman and her partner after informed consent. In most
cases, blood samples were further collected at M6, M12, and M18.
PBMC were isolated by centrifugation through lymphocyte
separation medium (GE Healthcare, Amersham) and either
immediately used or frozen in fetal calf serum (FCS)-10% DMSO
and stored at –180uC in liquid nitrogen.
HPV Typing
DNA extraction from keratinocytes obtained by genital
brushing (men) or biopsy (women) was performed using the High
Pure PCR Template KitH (Roche). HPV infection was determined
by PCR using the Universal L1 gene primers My09 and My11
[31]. Specific infection by HPV16 and HPV18 was assessed by
specific primers. Positive and negative controls were DNA from an
infected patient and water, respectively. PCR products were
analyzed on 1.5% agarose gels, purified with ExoSapIt purification
kitH (Amersham) and sequenced using the BigDyeH Terminator v
1.1 cycle sequencing Kit (Appelera) on Sequencer Applied
Biosystem 3130 XL ABI Prism 16 capillaries. The sequences
were identified using the Basic Local Alignment Search Tool
(BLAST) Nucleotid Algorithm.
HPV16 Serological Assay
Flat-bottomed 96-well microplates (Nunc, Maxisorp) were
coated with 200 ng per well of native virus like particles
produced as previously described [32] in PBS1X-FCS10% at
37uC for 1 h. Sera were serially diluted from 1: 20 to 1: 2560
in PBS5X-FCS10%-2% Tween 20. After four washes with
PBS1X-0.1% Tween 20, peroxidase-conjugated anti-human IgG
Ab (Southern Biotech) diluted 1 : 20,000 was used in PBS5X-
FCS10%-2% Tween 20 to detect the binding of human IgG.
After four washes with PBS1X-0.1% Tween 20, revelation was
done by ortho-phenylenediamine and H2O2. Colored reaction
was stopped with 4N H2SO4 after 30 min at room tempera-
ture. Optic density (OD) was read at 490 nm. Every condition
was tested in duplicate. Endpoint antibody titers were deter-
mined as the last of serial 2-fold dilution that yielded a positive
result. The cut-off level above which absorbances were
considered positive was 0.20.
Synthetic Peptides
Fifty-three overlapping peptides (15 to 16-mer) (NeoMPS)
spanning the whole E2 protein (365 amino acids) were used.
Peptides were pooled as described in Table 3 (E2-1 to E2-11
pools).
T-cell Proliferation Assay
Proliferation assays were performed in quadruplicate with
PBMCs (2610
5/per well) as previously described [33] and the
median value of cpm was calculated. SI were calculated as counts
per minute (cpm) in peptide-stimulated cells/cpm in negative
control wells (without peptide). Proliferative responses with SI .3
were scored as positive, provided that cpm in the negative control
was above 500. Negative controls were PBMC cultured in RPMI
1640–10% heat-inactivated human AB serum. Positive controls
were PBMCs activated by phorbol myristate acetate and
ionomycine (Sigma).
Intracellular Cytokine Staining
Cells were incubated overnight at 37uC with 5 mM peptides
in RPMI 1640+10% heat-inactivated human AB serum.
Brefeldin A (Sigma, at 10 mg/ml final concentration) was added
for 4 h at 37uC. Cells were washed in PBS 5% FCS, stained
with CD4 Peridinin Chlorophyll Protein (PERCP, Becton
Dickinson BD, clone SK3), lysed and permeabilized in buffer
(BD) for 10 minutes. After washes, staining was performed for
30 minutes at room temperature in the dark using anti-IFNc-
FITC (BD, clone 25723.11) and anti-IL2-PE antibodies (BD,
clone 5344.111). Analyses were done with a FACSCalibur (BD
Bioscience). Flow cytometry data were analyzed with CellQuest
Pro. For each cytokine or cytokine combinations, results were
expressed as percent of cytokine-expressing cells in CD4 positive
T-cell subset and compared to negative controls. Positive control
antigens were a mixture of short and large influenza, Epstein-
bar virus and cytomegalovirus peptides (NeoMPS). Responses
were considered positive when the percentages of CD4+ T-cells
Table 2. Ex vivo IFNc ELISPOT responses in women and men
against HPV16, HPV2, HPV27 and HPV55 E2 309–323 peptide.
Number of SFC for 10
6 PBMCs ± standard deviation
A
Patient
Pool
E2-10
HPV 16
Peptide
309–323
HPV 2
Peptide
309–323
HPV 16
Peptide
309–323
HPV 27
Peptide
309–323
HPV 55
F # 3 8096150 –
B 845678 – –
F # 48 5 618 – 250652 – –
F # 5 1692648 – 1692652 – –
F # 7 1399663 – 1613636 – –
F # 8 10216452 – 9906129 – –
M # 3 160618 – 114654 – –
M # 4 13076243 – 1487618 – –
M # 5 1117663 – 1117631 – –
M # 6 334628 – 6636142 – –
M # 7 1697653 – 1463643 – –
M # 8 10336306 – 2666109 – –
A: number of SFC in negative control was substracted.
B: number of SFC was ,3-fold the mean number of SFC in the negative control.
doi:10.1371/journal.pone.0036651.t002
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1 234567891 0 1 1 1 2 1 3 1 4 1 5 1 6
E2-1 1–15 M E T L C Q R L N V C Q D K I
5–20 C Q R L N V C Q D K I L T H Y E
13–28 D K I L T H Y E N D S T D L R D
24–39 T D L R D H I D Y W K H M R L E
30–44 I D Y W K H M R L E C A I Y Y
E 2 - 2 3 4 – 4 8 K HM RLECAI YYKARE
40–54 C A I Y Y K A R E M G F K H I
47–61 R E M G F K H I N H Q V V P T
52–66 K H I N H Q V V P T L A V S K
56–70 H Q V V P T L A V S K N K A L
E2-3 60–74 P T L A V S K N K A L Q A I E
6 8 – 8 2 K ALQ AI ELQ LTLETI
73–88 I E L Q L T L E T I Y N S Q Y S
8 0 – 9 4 E TI YNSQYSNEKW TL
85–99 S Q Y S N E K W T L Q D V S L
E2-4 90–104 E K W T L Q D V S L E V Y L T
94–108 L Q D V S L E V Y L T A P T G
99–114 L E V Y L T A P T G C I K K H G
108–122 G C I K K H G Y T V E V Q F D
113–128 H G Y T V E V Q F D G D I C N T
E2-5 119–134 V Q F D G D I C N T M H Y T N W
127–141 N T M H Y T N W T H I Y I C E
132–146 T N W T H I Y I C E E A S V T
136–150 H I Y I C E E A S V T V V E G
143–157 A S V T V V E G Q V D Y Y G L
E2-6 150–164 G Q V D Y Y G L Y Y V H E G I
155–170 Y G L Y Y V H E G I R T Y F V Q
162–177 E G I R T Y F V Q F K D D A E K
166–180 T Y F V Q F K D D A E K Y S K
176–190 E K Y S K N K V W E V H A G G
E2-7 181–196 N K V W E V H A G G Q V I L C P
190–204 G Q V I L C P T S V F S S N E
197–211 T S V F S S N E V S S P E I I
203–217 N E V S S P E I I R Q H L A N
208–222 P E I I R Q H L A N H P A A T
E2-8 212–226 R Q H L A N H P A A T H T K A
225–239 K A V A L G T E E T Q T T I Q
236–250 T T I Q R P R S E P D T G N P
245–260 P D T G N P C H T T K L L H R D
254–268 T K L L H R D S V D S A P I L
E2-9 260–274 D S V D S A P I L T A F N S S
265–280 A P I L T A F N S S H K G R I N
277–291 G R I N C N S N T T P I V H L
286–301 T P I V H L K G D A N T L K C L
2 9 6 – 3 1 0 N TLKCLRYRFKKHCT
E2-10 301–315 L R Y R F K K H C T L Y T A V
309–323 C T L Y T A V S S T W H W T G
317–331 S T W H W T G H N V K H K S A
324–338 H N V K H K S A I V T L T Y D
E2-11 330–344 S A I V T L T Y D S E W Q R D
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presence of the peptide as compared to negative control. The
combination of the two cytokines allows quantifying single
producer (IFNc or IL2 only) and dual producer (IFNc and IL-
2) CD4+ T-cells [26].
Ex vivo ELISPOT Assay for Single Cell IFNc Release
IFNc ELISPOT assays were performed as previously
described [33]. Negative controls were PBMC incubated in
complete medium alone. Positive controls were phorbol
myristate acetate- and ionomycine-stimulated cells. Only large
spots with fuzzy borders were scored as IFNc-SFC. Responses
were considered significant when the mean number of SFC by
10
6 cells in the 3 experimental wells was .3-fold the mean
number of SFC in the negative control wells (PBMC alone) and
.30 SFC/10
6 cells.
Statistical Analysis
Fisher exact test was used to evaluate whether HPV-specific T-
cell proliferations are statistically different between the groups of
women with or without HPV-related symptoms.
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